Key result
Empagliflozin lowers peak aortic jet velocity ~1.3 m/s vs vehicle in aortic valve injury.
Why the study?
No pharmacological therapy is established to slow aortic stenosis progression, and the effects of the SGLT2 inhibitor empagliflozin on aortic valve fibrosis, calcification, and function preservation remained unclear.
Does empagliflozin suppress the progression of aortic valve fibrosis and calcification and preserve valve function in a murine aortic valve wire injury model?
RCT (n=30)
Randomized at week 2 to empagliflozin or vehicle
Does empagliflozin suppress the progression of aortic valve fibrosis and calcification and preserve valve function in a murine aortic valve wire injury model?
Empagliflozin attenuated aortic valve fibrosis, calcification, and hemodynamic progression in a mouse model of aortic valve injury, suggesting potential as a medical therapy for aortic stenosis.
Answers are grounded in this paper and cite their sources.
Empagliflozin attenuated progression in a murine model; leaves open translation to human aortic stenosis.
Background Aortic stenosis is a progressive disease characterised by advancing aortic valve fibrosis and calcification. However, no pharmacological therapy has been established to slow valve disease progression. While the SGLT2 inhibitor empagliflozin has demonstrated significant cardiovascular benefits, its effects on aortic valve fibrosis, calcification, and function preservation remains unclear. Purpose This study aimed to determine whether empagliflozin suppresses the progression of aortic valve fibrosis and calcification and preserves valve function in a murine aortic valve wire injury (AVWI) model. Methods Male C57BL/6 mice aged 8–12 weeks were assigned to three groups (n=10 per group): sham, AVWI+vehicle, and AVWI+empagliflozin. AVWI was induced by inserting a 0.014-inch guidewire via the right carotid artery to injure the aortic valve, and sham mice underwent the same surgical procedure without wire-induced valve injury. At week 2, AVWI mice with a peak aortic jet velocity (PeakV) >2.0 m/s were randomized to receive empagliflozin (3 mg/kg/day via osmotic pump) or vehicle. Echocardiography was performed at baseline and at weeks 2, 4, 8, and 12. At week 12, the aortic valves were harvested for histological and immunohistochemical analyses (H&E, Masson’s trichrome, Sirius Red, von Kossa, RUNX2, and αSMA). Data are presented as mean±SD. Results Following AVWI, PeakV increased by week 2, reaching 2.39±0.24 m/s in the empagliflozin group and 2.37±0.29 m/s in the vehicle group at week 2 (P = 0.91) (sham 1.17±0.12 m/s). After week 4 onward, PeakV remained stable in the empagliflozin group, but continued to rise in the vehicle group (P<0.001 for group-by-time interaction). At week 12, PeakV was significantly lower in the empagliflozin group than in the vehicle group (2.00±0.41 m/s vs. 3.33±0.60 m/s, P < 0.001; sham 1.27±0.20 m/s). Empagliflozin also attenuated the increases in relative wall thickness (0.50±0.06 vs. 0.58±0.08, P = 0.021; sham 0.44±0.03) and heart weight-to-body weight ratio (3.12±0.25 mg/g vs. 3.95±0.99 mg/g, P = 0.028; sham 2.52±0.24 mg/g). Histological analysis demonstrated that empagliflozin reduced AVWI-induced increases in valve area and leaflet thickness. Furthermore, empagliflozin was found to attenuated fibrosis remodelling (Masson’s trichrome and Sirius Red) and calcification (von Kossa) while reducing the expression of RUNX2 and αSMA, as determined by immunohistochemical analysis, compared with the vehicle group. Conclusions Empagliflozin suppresses aortic valve fibrosis and calcification, preventing the deterioration of valve function in a murine AVWI model. These findings suggest that empagliflozin may be a promising pharmacological strategy for attenuating the progression of fibrotic and calcific aortic valve disease.
No takes yet. Share an insight, caveat, or question.
Ohmori et al. (2026) conducted an RCT in Aortic valve fibrosis and calcification (murine aortic valve wire injury model) (n=30). Empagliflozin vs. Vehicle (and sham control) was evaluated on Peak aortic jet velocity (PeakV, m/s) at week 12 (p=<0.001). Empagliflozin lowered week-12 peak aortic jet velocity compared with vehicle in mice with aortic valve wire injury.
Synapse has enriched 10 related papers. Consider them for comparative context: